Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Trametinib in GNAQ or GNA11 Mutated Tumors (MATCH Subprotocol S2)
NCT04439357Phase 2Active, not recruiting
- Sponsor
- National Cancer Institute
- Start
- Feb 2016
- Primary completion
- Sep 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of trametinib in malignant solid neoplasm, lymphoma and multiple myeloma (MM), sponsored by National Cancer Institute. Primary endpoint: Objective Response Rate up to 3 years. Started Feb 2016; status: active, not recruiting.
02
Drugs
trametinib
03
Conditions
malignant solid neoplasmlymphomamultiple myeloma (MM)
Beyond the preview
Go deeper on NCT04439357.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04439357.